Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
Authors:
Open Access
- 1 January 2013
- journal article
- review article
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. 7, 13-32
Abstract
Proteasomal inhibition revolutionized myeloma therapies in this decade of novel agents. The only US Food and Drug Administration approved proteasome inhibitor so far, bortezomib effectively targets the constitutive proteasome subunit ß5 of the 26S proteasome. Bortezomib induces high and quality response rates that are durable. However, myeloma cells acquire resistance to bortezomib through various mechanisms. Further, grade 3/4 peripheral neuropathy is seen in up to a quarter of patients treated with bortezomib. While the recent change in the mode of administration via the subcutaneous route is associated with a lower incidence of grade 3/4 peripheral neuropathy, it remains a major concern. The second generation proteasome inhibitors are promising, with increased preclinical efficacy and a better administration schedule. The current review spotlights the second generation proteasome inhibitors with special focus on the safety and efficacy of carfilzomib, an epoxyketone with lesser peripheral neuropathy, which exhibits irreversible proteasome inhibition. In this article, we review the pharmacology and preclinical and clinical efficacy and safety of carfilzomib alone and in combination with other chemotherapeutic agents in the various lymphoid neoplasms and multiple myeloma as well as ongoing clinical trials.Keywords
This publication has 79 references indexed in Scilit:
- Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells In Vitro and In VivoMolecular Cancer Therapeutics, 2011
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaBlood, 2010
- Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaBlood, 2010
- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoBlood, 2010
- Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myelomaBlood, 2010
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple MyelomaClinical Cancer Research, 2009
- Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelomaBlood, 2007
- The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cellsBritish Journal of Haematology, 2007
- A novel proteasome inhibitor NPI-0052 as an anticancer therapyBritish Journal of Cancer, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006